Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Common Equity (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Common Equity data on record, last reported at $776.7 million in Q3 2025.

  • For Q3 2025, Common Equity rose 6.74% year-over-year to $776.7 million; the TTM value through Sep 2025 reached $776.7 million, up 6.74%, while the annual FY2024 figure was $732.3 million, 14.53% up from the prior year.
  • Common Equity reached $776.7 million in Q3 2025 per AMPH's latest filing, up from $757.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $776.7 million in Q3 2025 and bottomed at $430.2 million in Q3 2021.
  • Average Common Equity over 5 years is $595.3 million, with a median of $589.2 million recorded in 2023.
  • Peak YoY movement for Common Equity: dropped 4.61% in 2021, then increased 22.56% in 2024.
  • A 5-year view of Common Equity shows it stood at $445.5 million in 2021, then grew by 18.66% to $528.7 million in 2022, then rose by 20.95% to $639.4 million in 2023, then grew by 14.53% to $732.3 million in 2024, then rose by 6.07% to $776.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $776.7 million in Q3 2025, $757.5 million in Q2 2025, and $751.3 million in Q1 2025.